Bio-Gate AG signs LOI with North American medical device manufacturer for trauma implants

EQS-News: Bio-Gate AG / Key word(s): Incoming Orders/Letter of Intent Bio-Gate AG signs LOI with North American medical device manufacturer for trauma implants 31.07.2023 / 17:01 CET/CEST The issuer is solely responsible for the content of this announcement.   PRESS INFORMATION   Bio-Gate AG signs LOI with North American medical device manufacturer for trauma implants   Nuremberg/Bremen, July 31, 2023 - Bio-Gate AG (ISIN DE000BGAG981), a leading provider of innovative technologies and individual solutions for health and hygiene, has concluded a preliminary agreement (LOI, Letter-of-Intent) with a North American medical device manufacturer focusing on the trauma sector. The medical device manufacturer intends to use Bio-Gate's "HyProtectTM" coating process for its own implants in human medicine following the FDA approval process.   With the North American medical device manufacturer, Bio-Gate has gained another important company as a partner for its "HyProtect" coating technology and can develop significant growth potential in applications for human medicine in the future. The repeatedly documented interest in Bio-Gate’s „HyProtect“ coating is a strong evidence of the high relevance of the technology.   Bio-Gate uses the "HyProtect" technology to coat medical devices with an ultra-thin layer containing polysiloxane and silver. The release of silver ions provides an antibacterial effect without altering product properties such as biocompatibility or biomechanical behavior. The infection data on the use of "HyProtect" is very positive, especially for implants in individual cases in human medicine and also for serial production implants in veterinary medicine.     Investor Relations Bio-Gate AG / Gerd Rückel Neumeyerstr. 28-34 D-90411 Nürnberg [e-mail] Tel. [phone] Mobil [phone] Press Bio-Gate AG Neumeyerstr. 28-34 D-90411 Nürnberg [e-mail] Tel. [phone]   About Bio-Gate AG Bio-Gate AG is a medical technology company that develops and markets applications which use unique silver technology to help prevent infections and thus to improve health. Bio-Gate AG’s specialty is using pure silver to treat materials and surfaces that are used in all areas of daily life – thus providing long-term and medically effective protection against bacteria, microorganisms and other pathogens. Bio-Gate AG works in three fields to supply a variety of products that provide antimicrobial protection: material enhancement, surface coatings and testing the antimicrobial or anti-adhesive properties of materials. The Nuremberg-based company offers systems that stretch across the entire value chain, from development to approval to production. For more information, please visit www.bio-gate.de.   Disclaimer This publication constitutes neither an offer to sell nor an invitation to buy securities. The shares in Bio-Gate AG (the “Shares”) may not be offered or sold in the United States or to or for the account or benefit of “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”)). The securities have already been sold. 31.07.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com

Language:	English
Company:	Bio-Gate AG
	Neumeyerstr. 28-34
	90411 Nürnberg
	Germany
Phone:	+49 (0) 911 / 47 75 23 – 100
Fax:	+49 (0) 911 / 47 75 23 – 101
E-mail:	[e-mail]
Internet:	www.bio-gate.de
ISIN:	DE000BGAG981
WKN:	BGAG98
Listed:	Regulated Unofficial Market in Berlin, Frankfurt, Munich (m:access), Stuttgart
EQS News ID:	1692375

End of News	EQS News Service

1692375  31.07.2023 CET/CEST